Skip to main content
Premium Trial:

Request an Annual Quote

Celera Signs Genset, Three Academic Institutions as Database Subscribers

NEW YORK, Jan 10 – Celera Genomics said Wednesday that it has signed multi-year subscriptions to its database products with three international academic institutions. Separately, Celera announced that Genset has signed a multi-year subscription agreement to Celera's databases, bioinformatics systems, and other tools.

The four new agreements bring Celera’s total number of current subscribers to 20.

Under the terms of the three academic agreements, the Max Planck Society for Advancement of Science in Germany, the Karolinska Institutet in Sweden, and the University of Tokyo in Japan will access Celera's database information through its web-based Discovery System.

Under the terms of the Genset agreement, Genset researchers will also access Celera's products through the Discovery System.

Financial terms of the agreements were not disclosed.

Craig Venter, Celera’s president and chief scientific officer, said that the academic agreements “are important in that an increasing number of researchers around the globe now have access to Celera's genomic and biological data and proprietary tools directly from their desktop."

Venter called the agreement with Genset, “an example of the ways that Celera intends to build the capabilities necessary to participate in the drug discovery and development process."

The Max Planck Society, Munich, Germany, is an independent, non-profit scientific research organization that carries out research in a number of fields. The Karolinska Institutet is Sweden's leading medical university and houses the Nobel Assembly and Nobel Committee responsible for selecting the annual Nobel laureate in physiology or medicine. The University of Tokyo is the oldest national university in Japan and its research activities cover a broad area of the medical sciences.

Genset, Nouveau March, France, is a genomics company that aims to generate a pipeline of drug candidates for the treatment of central nervous system and metabolic disorders.

Celera’s existing database subscribers include Pfizer, Takeda, American Home Products, Immunex, Valigen, Vanderbilt University, Harvard University, the University of Texas-Southwestern, University of Cincinnati/Children's Hospital of Cincinnati, Ohio State University, the government of Australia, Howard Hughes Medical Institute, TIGR, Weizmann Institute of Science, Hospital for Sick Children-Toronto, and the California Institute of Technology.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.